Preservation of renal function in liver transplant recipients with Certican therapy: PROTECT study A twelve-month, multicenter, randomized, open-label study of safety, tolerability and efficacy of Certican-based regimen versus calcineurin inhibitor-based regimen in de novo liver transplant recipients

Trial Profile

Preservation of renal function in liver transplant recipients with Certican therapy: PROTECT study A twelve-month, multicenter, randomized, open-label study of safety, tolerability and efficacy of Certican-based regimen versus calcineurin inhibitor-based regimen in de novo liver transplant recipients

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Tacrolimus
  • Indications Liver transplant rejection
  • Focus Adverse reactions; Registrational
  • Acronyms PROTECT
  • Sponsors Novartis Pharma
  • Most Recent Events

    • 24 Oct 2017 Pooled results assessing long-term clinical outcomes in patients with autoimmune liver diseases from two phase III trials (H2304 and PROTECT; n=23) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 10 May 2016 Results of a five year follow up study (n=81) published in the Clinical Transplantation.
    • 17 Feb 2014 Added related profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top